Adbry Dosage

Generic name: TRALOKINUMAB 150mg in 1mL
Dosage form: injection, solution
Drug class: Interleukin inhibitors

Medically reviewed by Drugs.com. Last updated on May 24, 2024.

Vaccination Prior to Treatment

Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with ADBRY.

Important Administration Instructions

ADBRY is administered by subcutaneous injection.
ADBRY is intended for use under the guidance of a healthcare provider. Provide proper training to patients and/or caregivers on the preparation and administration of ADBRY prior to use according to the "Instructions for Use".

Use of the Autoinjector

The ADBRY autoinjector is for use in adults only.
A caregiver or adult patient may inject ADBRY using the autoinjector.

Use of the Prefilled Syringe

The ADBRY prefilled syringe is for use in adults and pediatric patients 12 years of age and older.
A caregiver or patient 12 years of age and older may inject ADBRY using the prefilled syringe. In pediatric patients 12 years of age and older, administer ADBRY under the supervision of an adult.

Administration Instructions

Administer subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel. The upper arm can also be used if a caregiver administers the injection.
DO NOT inject ADBRY into skin that is tender, damaged, bruised, or scarred.
For adults taking the initial loading dose of 600 mg, administer each of the injections (four ADBRY 150 mg injections using prefilled syringes or two ADBRY 300 mg injections using autoinjectors) at different injection sites within the same body area.
- For the subsequent 300 mg doses using the prefilled syringe, administer the two ADBRY 150 mg injections at different injection sites within the same body area, rotating the body area with each subsequent set of injections.
- For the subsequent 300 mg doses using the autoinjector, administer one ADBRY 300 mg injection, rotating the body area with each subsequent injection
For pediatric patients 12 years of age and older taking the initial loading dose of 300 mg, use prefilled syringes to administer the two ADBRY 150 mg injections at different injection sites within the same body area.
- For the subsequent 150 mg doses, use a prefilled syringe to administer one ADBRY 150 mg injection, rotating the body area with each subsequent injection.
The ADBRY "Instructions for Use" contains more detailed instructions on the preparation and administration of ADBRY.

Recommended Dosage

Dosage in Adults

The recommended dosage for adults is:

	Initial Loading Dose	Subsequent Dosage
Prefilled syringe	600 mg (four 150 mg injections)	300 mg (two 150 mg injections) every other week
Autoinjector	600 mg (two 300 mg injections)	300 mg (one 300 mg injection) every other week

After 16 weeks of treatment, for adult patients with body weight below 100 kg who achieve clear or almost clear skin, a dosage of 300 mg every 4 weeks may be considered.

Dosage in Pediatric Patients 12 Years of Age and Older

The recommended dosage for pediatric patients 12 years of age and older is:

	Initial Loading Dose	Subsequent Dosage
Prefilled syringe	300 mg (two 150 mg injections)	150 mg (one 150 mg injection) every other week

Concomitant Topical Therapies

ADBRY can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas.

Missed Doses

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.

Preparation for Use

Before injection, remove ADBRY prefilled syringes or autoinjectors from the refrigerator and allow to reach room temperature (at least 30 minutes for the prefilled syringes and at least 45 minutes for the autoinjectors) without removing the needle cover or cap, respectively.
After removal from the refrigerator, ADBRY may be kept at room temperature up to 30°C (86°F) and must be used within 14 days or discarded.
Inspect ADBRY visually for particulate matter and discoloration prior to administration. ADBRY injection is a clear to opalescent, colorless to pale yellow solution. Do not use if the liquid contains visible particulate matter, is discolored or cloudy (other than clear to opalescent, colorless to pale yellow).
ADBRY does not contain preservatives; therefore, discard any unused product.